[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100237525":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":29,"centralContacts":34,"locations":40,"responsibleParty":57,"collaborators":38,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":64,"acronym":38,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":38,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":38,"overallStatus":42,"whyStopped":38,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"University of Alabama at Birmingham","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"670 nm light","EXPERIMENTAL","Subjects will have baseline blood flow measured in the gastrocnemius using octafluoropropane infusion and ultrasound.After baseline flow measurements are obtained, a 670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW\u002Fcm2. Contrast images will be obtained up to 5 minutes after the commencement of light.",[13,14],"Device: 670 nm light","Drug: octafluropropane",[16,22],{"type":17,"name":9,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW\u002Fcm2.",[9],[21],"Red light",{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","octafluropropane","Octofluoropropane will be administered as a continuous infusion prior to the initiation of 670 nm light in order to measure skeletal muscle blood flow.",[9],[28],"Definity",[30],{"name":31,"affiliation":32,"role":33},"Nicole L Lohr, MD, PhD","Medical College of Wisconsin","PRINCIPAL_INVESTIGATOR",[35],{"name":31,"role":36,"phone":37,"phoneExt":38,"email":39},"CONTACT","205-996-3504",null,"nlohr@uabmc.edu",[41],{"facility":32,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Milwaukee","Wisconsin","53226","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-87.90647,43.0389,{"lat":52,"lon":51},[55],{"name":56,"role":36,"phone":37,"phoneExt":38,"email":39},"Nicole L Lohr, MD PhD",{"type":33,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":38,"oldOrganization":38},"Nicole Lohr","Professor","100237525","peripheral-blood-flow-responses-to-electromagnetic-energy-100237525",false,"NCT02370199","Peripheral Blood Flow Responses to Electromagnetic Energy","Inclusion Criteria:\n\n* Participants will be healthy subjects over the age of 18.\n* Men and women will be recruited for participation.\n* All ethnicities will be included in this study.\n\nExclusion Criteria:\n\nExclusionary criteria include:\n\n* age under 18 years and those over 60 years of age,\n* those who are unable to understand the consent process,\n* those who cannot read or speak English,\n* a history of cancer,\n* peripheral artery disease,\n* diabetes mellitus,\n* active pregnancy,\n* hypersensitivity to perflutren contrast agents,\n* pulmonary hypertension,\n* chronic kidney disease,\n* active tobacco or drug use,\n* blood pressure over 160\u002F90, BMI\\>30,\n* sickle cell disease, or\n* history of intracardiac shunt.\n\nAdditional exclusion criteria include:\n\n* a history of coronary artery disease,\n* heart failure,\n* the presence of an implanted defibrillator or pacemaker,\n* a history of heart murmur or rhythm disorder (atrial fibrillation, atrial tachycardia, or ventricular tachycardia),\n* neurological diseases such as stroke, and\n* any uncontrolled medical conditions.",true,"ALL","18 Years","59 Years",{"count":71,"type":72},40,"ESTIMATED","INTERVENTIONAL",[75],"NA","This study evaluates 670 nm energy in the form of red light to stimulate blood flow changes in healthy adults. All participants will receive red light to their leg. They will also receive a continuous infusion of Definity (octafluoropropane) ultrasound contrast.",[78],"Exposure to Man-made Visible Light","2026-04-27",{"date":81,"type":82},"2026-05-01","ACTUAL",{"date":84,"type":38},"2014-11",{"date":86,"type":72},"2027-12-31",{"name":5,"class":6},1]